Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (November 15-19).
For detailed information, see the below URL.
aasld.org/sites/default/files/2024-10/1_the_liver_meeting_2024_abstracts.pdf
Poster #1060
The beneficial effect of resmetirom on tumorigenesis associated with MASH in STAM mice
Institution: Kurume University School of Medicine (Japan)
Poster #1082
Impact of ex-vivo expanded CD34-positive cells on tumor formation in hepatocarcinogenic mice with metabolic dysfunction-associated steatohepatitis
Institution: Kurume University School of Medicine (Japan)
Poster #3201
SQ1, mitochondria-targeted ferroptosis inhibitor, demonstrates efficacy against steatosis, ballooning and fibrosis in preclinical models of MASH
Institution: Mitotech Ltd. (UK)
For more information about the exam, please contact us.